Latest Articles
- Lipoprotein ‘little a’: More than a little target in the management of cardiovascular risk?
Lipoprotein(a) was once believed to play no contributory role in the development of cardiovascular disease. That storyline has since flipped.
- Rethinking recovery in heart failure: Beyond improvement in left ventricular ejection fraction
The authors discuss 3 unresolved questions about de-escalating and escalating guideline-directed medical therapy in patients with improved ejection fraction.
- Teprotumumab for thyroid eye disease: A reality check
Initial enthusiasm for teprotumumab as therapy for thyroid eye disease has been tempered by longitudinal data suggesting that it often does not alter the natural disease course.
- Managing obesity in older adults
The goals of treating obesity in older adults are to ease its complications and improve functional status and quality of life, with or without weight loss.
- No surprise, all inflammation is not created equal as it relates to cardiovascular disease
It is accepted that inflammation is an important component of atherosclerotic cardiovascular disease, but have we found the right inflammatory target for pharmacologic therapy?
- Benign migratory glossitis
A 26-year-old woman presented with well-defined erythematous patches on her tongue that had developed over the previous 6 months.
- Nearly a century of using glucocorticoids in patients with active infection
Why would we consider dampening the immune response with glucocorticoids when a patient has an active infection?